Bioavailability Clinical Development Marketing 
Pharmaceutical Technology
AUGUST 30, 2022
Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.
Pharmaceutical Technology
MAY 31, 2023
It is expected to accelerate the development of CFT8919 in important international markets. CFT8919 is an orally bioavailable BiDAC degrader designed to exhibit potent and selective activity against EGFR L858R in patients with non-small cell lung cancer (NSCLC).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 23, 2022
While Restasis and Xiidra have been in use in the US market for a long time, both treatments have been associated with patient satisfaction issues such as a non-favorable tolerability profile and a slow onset of action. This gap in the market is what the late-stage pipeline therapies are currently targeting. Novaliq’s CyclASol (0.1%
Pharmaceutical Technology
OCTOBER 25, 2022
As the number of FDC products in development and coming to the market increase, the pharmaceutical industry is looking to FDCs as a promising strategy to repurpose, repackage, and expand indications for existing and novel therapeutic agents. Accelerated regulatory pathway. To find out more, download the whitepaper below.
pharmaphorum
AUGUST 19, 2022
If all goes well, the aim is to bring resiniferatoxin to market in 2025. Among these still in development, Glenmark’s orally active GRC17536 cleared a phase 2a study in diabetic neuropathy but has bioavailability issues that have held up a phase 3 programme.
Pharmaceutical Technology
JUNE 26, 2022
Placing traditionally siloed drug substance and drug product development activities within a single organization that also has commercial manufacturing capabilities accelerates clinical development and builds in quality and robustness of supply. Streamlined processes to reduce time to market for drugs.
The Pharma Data
JULY 12, 2021
“It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “If About Molnupiravir. About Ridgeback Biotherapeutics.
Expert insights. Personalized for you.
130 
Let's personalize your content